Clinical Trials · NCT01403025
Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 4,121
- Start date
- Jul 2011
- Locations
- 1 site, Japan
- Primary endpoint
- The incidence of SADRs (Serious Adverse Drug Reactions)